🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Get an email when a company you follow pushes back or drops a promised milestone. Included in the 7-day free trial.

Biotech Missed Milestones

Biotech companies tell investors when data, regulatory filings and trial starts will come. This page tracks those promises, word for word from their press releases filed with the SEC, and flags the windows that closed without an update.

In the last year BioRadar collected 5626 timing statements from 602 companies. Among the promised windows that closed in the last nine months, 16 were pushed back to a later date by the company itself, 4 ended with the program or trial discontinued, each shown with the company's own words before and after, and for 1 the company's later filings say nothing about the milestone at all. A slipped timeline is often the first public sign of trouble with enrollment, manufacturing or data, and it moves the date a trade depends on.

16Pushed back
4Discontinued
1No update found
602Companies tracked
5626Timing statements, last year

How to read this. Each row is a promise in the company's own words, with the date it was made and a link to the filing, next to what the company said later: a newer date for the same milestone, or the end of the program. Every row carries both quotes, so you can check it in one click. Full method

Limits. Only filings on SEC EDGAR are read: press releases and quarterly and annual reports (10-Q, 10-K). Earnings calls, conference talks and company websites are not. A no update found row means those filings are silent 45 days after the window closed; the company may have reported elsewhere, so treat it as a question to ask, not as proof of a delay. Deliveries are not listed. Vague windows (“in the coming months”) and statements that name no trial, drug code or drug are not judged.

Press releases checked daily on SEC EDGAR. Last update Nov 17, 2026, 04:41 UTC.

Pushed back to a later date

CompanyOriginal promiseWindowNewer statement
ANROAlto Neuroscience, Inc. Data or results · ALTO-300“ALTO-300 and ALTO-100 Ongoing Phase 2b Trials: Enrollment continues in the Phase 2b trial of ALTO-300 in Major Depressive Disorder (MDD), with topline data expected in mid-2026.”Company press release, Mar 16, 2026 · SEC filing mid-2026closed Sep 30, 2026, 48 days ago Now 1H 2027“Topline data are expected in 1H 2027 for ALTO-300 and mid-2027 for ALTO-100.”Company press release, Nov 10, 2026 · SEC filing
ANTXAN2 Therapeutics, Inc. Trial start · PV“PV is estimated to affect approximately 155,000 people in the U.S. The Company is proceeding through the regulatory process and plans to initiate the Phase 2 clinical trial in the third quarter of 2026.”Company press release, May 11, 2026 · SEC filing third quarter of 2026closed Sep 30, 2026, 48 days ago Now by year-end“Phase 2 global study of oral epetraborole in PV cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end Startup activities are underway for a global Phase 2 study to evaluate the efficacy and safety of oral epetraborole in adults with phlebotomy-dependent PV.”Company press release, Nov 9, 2026 · SEC filing
EQEquillium, Inc. Trial start · EQ504“Plans to initiate a Phase 1 proof-of-mechanism study in mid-2026, with data expected approximately six months thereafter.”Company press release, May 13, 2026 · SEC filing mid-2026closed Sep 30, 2026, 48 days ago Now fourth quarter of 2026“Advancing EQ504 toward the clinic, with the Phase 1 proof-of-mechanism study expected to initiate in the fourth quarter of 2026, and topline data anticipated approximately six months thereafter.”Company press release, Aug 13, 2026 · SEC filing
EXELEXELIXIS, INC. Data or results · STELLAR-304“Topline Results for STELLAR-304 Anticipated Mid-2026.”Company press release, Jan 12, 2026 · SEC filing Mid-2026closed Sep 30, 2026, 48 days ago Now first quarter of 2027“Zanzalintinib GU Highlights Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027.”Company press release, Oct 29, 2026 · SEC filing
GANXGain Therapeutics, Inc. Trial start · rexaceract“Phase 2 clinical trial of rexaceract in people with Parkinson’s disease expected to begin in Q3 2026.”Company press release, Aug 11, 2026 · SEC filing Q3 2026closed Sep 30, 2026, 48 days ago Now Q1 2027“Phase 2 clinical trial of rexaceract in people with Parkinson’s disease expected to begin in Q1 2027.”Company press release, Nov 10, 2026 · SEC filing
VTVTvTv Therapeutics Inc. Data or results · CATT1“The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026. vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point w…”Company press release, May 13, 2026 · SEC filing third quarter of 2026closed Sep 30, 2026, 48 days ago Now mid 2027“In October 2026, the Company announced completion of enrollment in its Phase 3 CATT1 trial and continues to expect topline results in mid 2027, and randomized the first participant in Hybrid CATT1, its Phase 2a study of cadisegliatin in individuals with T1D who use hybrid closed-loop insulin delivery systems.”Company press release, Nov 5, 2026 · SEC filing
ZURAZura Bio Limited Data or results · TibuSURE“Topline data are expected in the third quarter of 2026. · TibuSURE (SSc): The Phase 2 clinical trial in adults with SSc continued to advance during the quarter.”Company press release, Nov 13, 2025 · SEC filing third quarter of 2026closed Sep 30, 2026, 48 days ago Now H1 2027“Anticipated upcoming milestones The Company remains committed to the ongoing TibuSURE study of tibulizumab in systemic sclerosis, with topline data expected in H1 2027, and to the planned NEXUS-PMR study in polymyalgia rheumatica, with data expected in Q4 2028.”Company press release, Nov 9, 2026 · SEC filing
ACETAdicet Bio, Inc. Regulatory submission · ADI-212“Adicet expects to submit a regulatory filing for ADI-212 for the treatment of mCRPC in the first half of 2026.”Company press release, Jan 7, 2026 · SEC filing first half of 2026closed Jun 30, 2026, 140 days ago Now third quarter of 2026“Beyond prula-cel, we expect to submit a regulatory filing for ADI-212 for the treatment of mCPRC in the third quarter of 2026 with enrollment expected to begin in the fourth quarter of 2026.”Company press release, Mar 12, 2026 · SEC filing
GNPXGenprex, Inc. Enrollment · the Phase 2 expansion portion of the study“The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expects the interim analysis in the second half of 2026.”Company press release, Feb 23, 2026 · SEC filing first half of 2026closed Jun 30, 2026, 140 days ago Now by the end of 2026“We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study by the end of 2026 and expect the interim analysis in the first half of 2027.”Company press release, Jul 14, 2026 · SEC filing
KPTIKaryopharm Therapeutics Inc. Data or results · XPORT-MM-031 (EMN29)“The Company expects to report top-line data from this event-driven trial in the first half of 2026.”Company press release, Nov 3, 2025 · SEC filing first half of 2026closed Jun 30, 2026, 140 days ago Now second half of 2026“Announce topline data from the event-driven Phase 3 XPORT-MM-031 (EMN29) trial expected in the second half of 2026. 2026 Financial Outlook Based on its current operating plans, Karyopharm expects the following for full year 2026:”Company press release, Aug 13, 2026 · SEC filing
KRYSKrystal Biotech, Inc. Trial start · KB304“Jeune Aesthetics, Inc. (Jeune), a wholly-owned subsidiary of the Company, remains on track to initiate a Phase 2 study of its lead program KB304 in 1H 2026 following feedback from the FDA on Jeune’s validated décolleté-specific photonumeric scale and Phase 2 study design in 2H 2025.”Company press release, Nov 3, 2025 · SEC filing 1H 2026closed Jun 30, 2026, 140 days ago Now in 2027“The Company expects to initiate a Phase 2 study of its lead program KB304 in 2027.”Company press release, Nov 2, 2026 · SEC filing
NMRANeumora Therapeutics, Inc. Trial start · NMRA-215“NMRA-215: Plans to initiate Phase 1 clinical program following class-leading preclinical data Neumora expects to initiate a clinical program evaluating NMRA-215 monotherapy and combination therapy for the treatment of obesity in the first half of 2026.”Company press release, Jan 5, 2026 · SEC filing first half of 2026closed Jun 30, 2026, 140 days ago Now by End of 2026“KEY PIPELINE HIGHLIGHTS NMRA-215 (NLRP3 Inhibitor): Phase 1 Study Expected to Initiate by End of 2026 Neumora is developing NMRA-215 for the treatment of obesity and cardiometabolic disease.”Company press release, Aug 14, 2026 · SEC filing
QUREuniQure N.V. Data or results · AMT-260“In parallel, following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter and evaluating additional international opportunities.” “We expect to deliver key clinical updates throughout 2026, including data from our AMT-260 program in refractory mesial temporal lobe epilepsy …”Company press release, May 5, 2026 · SEC filing second quarterclosed Jun 30, 2026, 140 days ago Now first half of 2027“Continued clinical progress in pipeline programs AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE) · In the third quarter of 2026, the Company completed enrollment in the second dose cohort of seven patients in the ongoing Phase I/IIa study and expects to present updated results in the first …”Company press release, Nov 4, 2026 · SEC filing
QUREuniQure N.V. Data or results · Phase I/IIa clinical trial“The Company expects to present updated results from the Phase I/IIa clinical trial in the first half of 2026.”Company press release, Nov 10, 2025 · SEC filing first half of 2026closed Jun 30, 2026, 140 days ago Now first half of 2027“uniQure expects to present updated results from the Phase I/IIa clinical trial in the first half of 2027.”Company press release, Jun 22, 2026 · SEC filing
SNDXSyndax Pharmaceuticals, Inc. Data or results · revumenib“New/updated data expected in the second quarter of 2026:”Company press release, Apr 30, 2026 · SEC filing second quarter of 2026closed Jun 30, 2026, 140 days ago Now fourth quarter of 2026“The Company expects to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:”Company press release, Nov 2, 2026 · SEC filing
TENXTENAX THERAPEUTICS, INC. Enrollment“Based on these results, Tenax confirmed the target enrollment remains unchanged, and reiterated that enrollment is expected to complete in the first half of 2026.”Company press release, Dec 17, 2025 · SEC filing first half of 2026closed Jun 30, 2026, 140 days ago Now by the end of 2027“We expect to complete LEVEL-2 enrollment by the end of 2027.”Company press release, Jul 31, 2026 · SEC filing

Discontinued

CompanyOriginal promiseWindowWhat the company said later
LKFTLakefront Biotherapeutics NV Data or results · GALACELA SLE study with GLPG3667“The GALACELA SLE study with GLPG3667 is currently ongoing, and the final Week 48 data are expected in the second quarter of 2026.”Company press release, May 6, 2026 · SEC filing second quarter of 2026closed Jun 30, 2026, 140 days ago Discontinued“GLPG3667 discontinuation: Lakefront has completed a rigorous analysis of the competitive landscape and market opportunity.”Company press release, Nov 12, 2026 · SEC filing
MBXMBX Biosciences, Inc. Data or results · imapextide (MBX 1416)“Phase 2a trial of imapextide (MBX 1416) ongoing: Results from the ongoing Phase 2a STEADI TM trial of potential once-weekly imapextide for post-bariatric hypoglycemia are expected in Q2 2026.”Company press release, Mar 12, 2026 · SEC filing Q2 2026closed Jun 30, 2026, 140 days ago Discontinued“we will not be committing further investment toward a Phase 2b trial of imapextide in PBH.”Company press release, May 11, 2026 · SEC filing
NMRANeumora Therapeutics, Inc. Data or results · navacaprant“Navacaprant: Enrollment Ongoing in Phase 3 KOASTAL Program; Topline Data Expected in 1H 2026 The Company is on track to report topline data with navacaprant in MDD from KOASTAL-3 in the first quarter of 2026 and KOASTAL-2 in the second quarter of 2026.”Company press release, Nov 6, 2025 · SEC filing second quarter of 2026closed Jun 30, 2026, 140 days ago Discontinued“Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant”Company press release, Jun 15, 2026 · SEC filing
TCRXTScan Therapeutics, Inc. Data or results · PLEXI-T“Plans to share safety and efficacy data on patients infused to date in the PLEXI-T solid tumor trial in the first quarter of 2026.”Company press release, Nov 12, 2025 · SEC filing first quarter of 2026closed Mar 31, 2026, 231 days ago Discontinued“In November 2025, the Company announced the discontinuation of the PLEXI-T™ trial.”Company press release, Mar 4, 2026 · SEC filing

Window closed, no update found

The window closed at least 45 days ago. BioRadar read every press release the company filed since then and its newest quarterly or annual report, and none says the milestone happened, got a new date or was stopped.

CompanyOriginal promiseWindowWhat was checked
SDGRSchrodinger, Inc. Trial start · aleniglipron“Structure expects to initiate the aleniglipron Phase 3 program in mid-2026.”Company press release, Feb 25, 2026 · SEC filing mid-2026closed Sep 30, 2026, 48 days ago No update found Nothing on it in the press release filed since the window closed, or in the Form 10-Q. Form 10-Q, Nov 4, 2026 · SEC filing

How this works

Source. Every day BioRadar reads the press releases that biotech and pharma companies file with the SEC as exhibits to Form 8-K (Items 2.02, 7.01 and 8.01) or Form 6-K. A sentence is kept as a promise only if it has a forward-looking verb (expects, anticipates, plans to), a milestone (data, topline results, a BLA or NDA submission, enrollment, a trial start) and a timing phrase such as “fourth quarter of 2026” or “by year-end”. The forward-looking-statements boilerplate at the end of each release is ignored. Sentences are stored word for word; no model rewrites them.

Window. The timing phrase sets the last day of the window: “Q4 2026” ends December 31, 2026, “first half of 2027” ends June 30, 2027 and “in 2026” ends December 31, 2026.

Status. After the window closes, later releases from the same company are checked. Pushed back: a newer statement gives the same milestone a later window, and the model has confirmed it is the same milestone and that it was not reported as done. Discontinued: a later release says the program, trial or plan was stopped. Milestones reported as done are not listed. The promise and the evidence must name the same trial (for example REGAL or ENGAGE) or, when no trial is named, the same drug code or drug. A language model first confirms that each statement is a concrete clinical or regulatory milestone and which program it names. Where the rules find no evidence, the model reads the company's later releases and must quote the sentence that shows a report, a new date or a discontinuation; the quote is checked word for word against the filing before it is shown. If the releases are silent, it also reads every passage that names the program in the newest 10-Q or 10-K filed after the window. Only when both are silent, and 45 days have passed, is the window listed as no update found. When a company repeats a promise, only the newest statement is judged. Windows that closed more than nine months ago drop off the page.

Frequently asked questions

What is a missed milestone in biotech?

A missed milestone is a date a company gave investors for data, a regulatory submission, full enrollment or a trial start that passed without the company reporting it or giving a new date. It often signals slower enrollment, manufacturing work or a changed plan.

Where do these promises come from?

From the companies' own press releases filed with the SEC as exhibits to Form 8-K or Form 6-K. Each row quotes the sentence word for word and links to the filing.

What does "no update found" mean?

The promised window closed at least 45 days ago, and neither the press releases the company filed with the SEC since then nor its newest quarterly or annual report says the milestone happened, got a new date or was stopped. Companies also report on earnings calls, at medical conferences and on their websites, so it is a question to ask the company, not proof of a delay.

How often is the page updated?

Daily. New press releases are read every morning and every closed window is re-checked against the company's later releases.

Is this investment advice?

No. It is a record of what companies said and whether their later filings show it happening. Always read the source filing.

Data: company press releases filed on SEC EDGAR • Informational only, not investment advice.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.

⚠️ This data is for informational purposes only, not investment advice. Always do your own research.